Definium Therapeutics (DFTX) Total Liabilities (2019 - 2026)

Definium Therapeutics (DFTX) has 8 years of Total Liabilities data on file, last reported at $122.4 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $122.4 million, up 133.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $122.4 million (up 133.15% YoY), and the FY2025 annual result was $107.8 million, up 77.54% from the prior year.
• Total Liabilities climbed to $122.4 million in Q1 2026 per DFTX's latest filing, from $107.8 million in the prior quarter.
• Over five years, Total Liabilities peaked at $122.4 million in Q1 2026 and troughed at $9.8 million in Q2 2022.
• A 5-year average of $56.1 million and a median of $52.5 million in 2025 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Liabilities jumped 269.52% in 2023, then tumbled 33.92% in 2025.
• A 5-year view of Total Liabilities shows it stood at $19.1 million in 2022, then soared by 143.27% to $46.4 million in 2023, then jumped by 30.81% to $60.7 million in 2024, then soared by 77.54% to $107.8 million in 2025, then rose by 13.61% to $122.4 million in 2026.
• Business Quant data shows DFTX's Total Liabilities at $122.4 million in Q1 2026, $107.8 million in Q4 2025, and $106.3 million in Q3 2025.